Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | JAK3 |
Variant | L857P |
Impact List | missense |
Protein Effect | gain of function |
Gene Variant Descriptions | JAK3 L857P lies within protein kinase domain 2 of the Jak3 protein (UniProt.org). L857P results in cytokine receptor complex-independent activation of Jak3, increased cell proliferation (PMID: 26446793), and cytokine-independent growth in culture (PMID: 35411095). |
Associated Drug Resistance | |
Category Variants Paths |
JAK3 mutant JAK3 act mut JAK3 L857P |
Transcript | NM_000215.4 |
gDNA | chr19:g.17832629A>G |
cDNA | c.2570T>C |
Protein | p.L857P |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
XM_047438786.1 | chr19:g.17832629A>G | c.2570T>C | p.L857P | RefSeq | GRCh38/hg38 |
NM_000215.4 | chr19:g.17832629A>G | c.2570T>C | p.L857P | RefSeq | GRCh38/hg38 |
NM_000215 | chr19:g.17832629A>G | c.2570T>C | p.L857P | RefSeq | GRCh38/hg38 |
NM_000215.3 | chr19:g.17832629A>G | c.2570T>C | p.L857P | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
JAK3 L857P | Advanced Solid Tumor | decreased response | Ruxolitinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells over expressing JAK3 L857P demonstrated reduced sensitivity to Jakafi (ruxolitinib) in culture (PMID: 26446793). | 26446793 |
JAK3 L857P | Advanced Solid Tumor | sensitive | NIBR3049 | Preclinical - Cell culture | Actionable | In a preclinical study, NIBR3049 inhibited Jak3-Stat signaling and cell proliferation in transformed cells over expressing JAK3 L857P in culture (PMID: 26446793). | 26446793 |
JAK3 L857P | Advanced Solid Tumor | sensitive | Tofacitinib | Preclinical - Cell culture | Actionable | In a preclinical study, Xeljanz (tofacitinib) inhibited Jak3-Stat signaling and cell proliferation in transformed cells over expressing JAK3 L857P in culture (PMID: 26446793). | 26446793 |